UPB at a glance
Upstream Bio, Inc. (UPB, SEC CIK 2022626) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 1, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Upstream Bio, Inc. (UPB) reported revenue of $2.9 million (up 20.4% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$2.66.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Upstream Bio, Inc. (UPB) shares worth $147.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ambrose Allison on September 16, 2026 of 485 shares at $5.49 per share.
- In the last 90 days, UPB insiders reported 0 open-market purchases ($0) and 5 open-market sales ($28K) on Form 4, a net sale of $28K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.9M
- +20.4% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$28K
- 13F holders
- 24 funds
- $147.2M · +2 vs prior quarter
- Latest 8-K
- Sep 1, 2026
- Item 7.01 · Item 8.01
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Verekitug Phase 3 plans announced for severe asthma and chronic rhinosinusitis with nasal polyps
- Development update signals advancement toward pivotal clinical testing and potential regulatory submissions
Item EX-99.1: Item EX-99.1
- Phase 3 trials planned for severe asthma and CRSwNP, marking verekitug’s transition into pivotal late-stage development
- 400mg subcutaneous dose every 12 weeks, targeting quarterly administration and broad populations regardless of biomarker status
Item 8.01: Other Events
- Verekitug Phase 3 plans target severe asthma and CRSwNP, advancing the asset toward pivotal efficacy and regulatory testing
- One 400mg subcutaneous dose every 12 weeks, with approximately 1,500 patients across both placebo-controlled trials
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results and business highlights announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operational details
Item EX-99.1: Item EX-99.1
- Phase 3 severe asthma and CRSwNP trials remain targeted for Q1 2027, preserving key clinical-development catalysts
- COPD Phase 2 enrollment completed with 481 participants; data expected in the second half of 2027
Item 5.07: Submission of Matters to a Vote of Security Holders
- 48,100,767 shares represented, establishing a quorum from 54,419,986 shares outstanding
- Class II directors Fleming and Ratcliffe elected through the 2029 annual meeting
AI summaries of UPB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for UPB
Don't miss the next UPB filing
- Alerts as it files. A push when UPB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut UPB, by share count.
- Ask anything. An AI agent that reads every UPB filing and answers with sources.
UPB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ambrose Allison | Sell | Sep 16, 2026 | 485 | $5.49 |
| GRAY MICHAEL | Sell | Sep 16, 2026 | 853 | $5.49 |
| Sutherland Everett Rand | Sell | Sep 16, 2026 | 2,095 | $5.49 |
| Houghton Adam | Sell | Sep 16, 2026 | 700 | $5.49 |
| Deykin Aaron | Sell | Sep 16, 2026 | 895 | $5.49 |
| Houghton Adam | Sell | Jun 16, 2026 | 700 | $6.10 |
| GRAY MICHAEL | Sell | Jun 16, 2026 | 853 | $6.10 |
| Deykin Aaron | Sell | Jun 16, 2026 | 895 | $6.10 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $2.4M | $2.4M | $2.9M |
| Operating Income | - | -$77.8M | -$160.4M |
| Net Income | - | -$62.8M | -$143.4M |
| Op. Margin | - | -3281.2% | -5618.8% |
| Net Margin | - | -2650.0% | -5026.0% |
| Balance Sheet | |||
| Total Assets | $117.2M | $481.7M | $353.8M |
| Equity | -$123.1M | $469.9M | $339.8M |
| ROE | - | -13.4% | -42.2% |
| Per Share | |||
| EPS | $-12.95 | $-5.58 | $-2.66 |
| Cash Flow | |||
| Operating CF | - | -$59.2M | -$133.3M |
| CapEx | - | $511K | $165K |
Source: XBRL data in Upstream Bio, Inc. (UPB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate UPB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $147.2M |
| Q1 2026 | 22 | $167.1M |
| Q4 2025 | 23 | $446.7M |
| Q3 2025 | 20 | $286.9M |
| Q2 2025 | 15 | $145.2M |
| Q1 2025 | 15 | $54.3M |
| Q4 2024 | 10 | $144.2M |
- JPMorgan Chase & Co+549.0K (+119%)
- AQR Capital Management+472.7K (+655%)
- BlackRock+382.7K (+11%)
- Bank of America Corp+343.3K (+708%)
- Dimensional Fund Advisors+301.6K (+377%)
- Goldman Sachs Group−69.7K (-22%)
- Morgan Stanley−28.0K (-5%)
- Vanguard Portfolio Management LLC−15.0K (-2%)
- U.S. Bancorp−326 (-55%)
- Two Sigma Investments+42.3K
- Ameriprise Financial+10.5K
- PNC Financial Services+387
- Franklin Resources−14.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 129 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
UPB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| SC 13G | Jul 30, 2026 | - | - | |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 8-K | Mar 26, 2026 | - | - | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
UPB SEC filings: frequently asked questions
Are UPB insiders buying or selling?
In the last 90 days, Upstream Bio, Inc. (UPB) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $27,604 by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold UPB stock?
As of June 30, 2026, the largest Upstream Bio, Inc. (UPB) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($56.5 million), BlackRock ($26.0 million), Vanguard Capital Management LLC ($13.0 million), Millennium Management ($7.9 million), D.E. Shaw & Co ($7.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was UPB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Upstream Bio, Inc. (UPB) reported revenue of $2.9 million (up 20.4% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$2.66. The figures come from the XBRL data in the 10-K.
What did UPB report in its latest 8-K?
Upstream Bio, Inc. (UPB) filed an 8-K on September 1, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Verekitug Phase 3 plans announced for severe asthma and chronic rhinosinusitis with nasal polyps.
What are the latest UPB SEC filings?
Upstream Bio, Inc. (UPB) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 1, 2026 and a Form 4 insider filing on September 17, 2026.
What is UPB's SEC CIK number?
Upstream Bio, Inc. (UPB)'s SEC Central Index Key (CIK) is 2022626. EDGAR lists every UPB filing under that number.
Ask anything about UPB
The research agent reads UPB's filings, financials, insider trades and 13F holders, then answers with sources.